BRD4 Inhibitor-25, a chemical compound targeting the BD1 and BD2 domains of BRD4 with half-maximal inhibitory concentrations (IC50s) of 0.82 μM and 1.94 μM respectively, demonstrates efficacy in inducing apoptotic and autophagic cell death in ovarian cancer cells. This compound is utilized in researching cancers, cardiovascular, neuromuscular, and inflammatory disorders.